Depression in Parkinson's Disease: Real-World Prescribing Patterns and Treatment Dynamics from a Nationwide Greek Cohort.

Authors

Vasilios Karageorgiou, Petros Skapinakis, Ioannis Michopoulos, Panagiota Mitrou, Eleftherios Thireos, Rossetos Gournellis

Published in

Movement disorders clinical practice. Sep 15, 2026. Epub Sep 15, 2026.

Abstract

Depression in Parkinson's disease (PD-DD) is common, but little is known for outcomes after antidepressants are started.
We examine prescribing patterns and treatment trajectories for depression in Parkinson's disease (PD) in a Greek nationwide cohort (IDYKA) of 28,370 PD-DD patients and 660,504 DD patients without PD.
Target trial emulation with propensity score weighting comparing SSRIs, non-SSRI antidepressants, atypical antipsychotics (AAPs), and benzodiazepines on discontinuation and switching/augmentation.
The PD-DD association (pooled OR 8.37, 95% CI 5.02-13.98) is age-dependent in both sexes. Clinicians favored sedative agents, particularly mirtazapine (age- and gender-adjusted OR [aOR] 1.26, 95% CI 1.22-1.30), duloxetine (1.41, 1.36-1.48), and quetiapine (1.33, 1.28-1.38). AAP were less commonly discontinued compared to SSRIs (HR 0.838 [0.771, 0.911]). Non-SSRI ADs were associated with higher switch/augmentation rates (1.155 [1.058, 1.240]).
In PD depression, AAP outlast SSRIs in real-world persistence and non-SSRIs are more commonly switched or augmented.

PMID:
42742618
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.